A Retrospective Pilot Study To Evaluate the Efficacy and Safety of Conjuran®(Polynucleotide) Compared to Hyruan Plus®(Sodium hyaluronate), Synovian®(BDDE cross-linked sodium hyaluronate) in Patients with Knee Osteoarthritis

The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 15 人开始时间: 待定最近更新: 2020年11月3日

适应症

试验速览

暂无简介。

•1) adult over 40 years old
•2) Knee osteoarthritis patients of Grade l-lll according to Kellgren-Lawrence grading scale
•3) 100mm VAS(visual analogue score) for pain during weight bearing more than 40mm in at least one joint of the bilateral knee joint

•1) patient with severe trauma or fracture history of the indicator knee joint
•2) Those with rheumatoid arthritis or other metabolid arthritis
•3) Patient with infection around the indicator knee joint
•4) Those who have joint replacement surgery in the indicator knee joint
•5) Those who have hip joint osteoarthritis in ipsilateral side of the indicator knee joint
•6) Patient with other disease that may affect the safety and effectiveness evaluation of the indicator knee joint (e.g., patients with severe pain, such as complex pain regional syndrome, Paget's disease, intervertebral disc prolapse, and gout, recurrent pseudogout)
•7) patient who received intra-articular hyaluronic acid injection within the previous three months of baseline(before study) or those who received intra-articular steroid injections within one month
•8) those who received anticoagulant or platelet aggregation inhibitors within one week prior to the baseline (before study)
•9) patient who received physiotherapy in the baseline (before study) within two weeks prior to the indicator knee joint

发起方

The Catholic University of Korea, Seoul St. Mary's Hospital